Publicacións en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (1)

2019

  1. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 6, pp. 1046-1060